1. Home
  2. TNXP vs PSF Comparison

TNXP vs PSF Comparison

Compare TNXP & PSF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tonix Pharmaceuticals Holding Corp.

TNXP

Tonix Pharmaceuticals Holding Corp.

HOLD

Current Price

$14.09

Market Cap

198.6M

Sector

Health Care

ML Signal

HOLD

Logo Cohen & Steers Select Preferred and Income Fund Inc.

PSF

Cohen & Steers Select Preferred and Income Fund Inc.

HOLD

Current Price

$19.42

Market Cap

231.7M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
TNXP
PSF
Founded
2007
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
198.6M
231.7M
IPO Year
2008
N/A

Fundamental Metrics

Financial Performance
Metric
TNXP
PSF
Price
$14.09
$19.42
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
366.4K
49.6K
Earning Date
05-11-2026
01-01-0001
Dividend Yield
N/A
7.69%
EPS Growth
91.75
N/A
EPS
N/A
N/A
Revenue
$13,107,000.00
N/A
Revenue This Year
$558.11
N/A
Revenue Next Year
$38.29
N/A
P/E Ratio
N/A
N/A
Revenue Growth
29.85
N/A
52 Week Low
$11.60
$18.95
52 Week High
$69.65
$21.20

Technical Indicators

Market Signals
Indicator
TNXP
PSF
Relative Strength Index (RSI) 51.94 40.12
Support Level $12.43 $18.95
Resistance Level $14.85 $20.61
Average True Range (ATR) 1.16 0.19
MACD 0.08 -0.06
Stochastic Oscillator 49.70 24.42

Price Performance

Historical Comparison
TNXP
PSF

About TNXP Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.

About PSF Cohen & Steers Select Preferred and Income Fund Inc.

Cohen & Steers Select Preferred and Income Fund Inc is a diversified, closed-end investment company. The Fund's primary investment objective is high current income with capital appreciation as its secondary objective. The Fund invests at least of its Managed Assets in preferred and other income securities issued by U.S. and non-U.S. companies.

Share on Social Networks: